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2Abstract
A sensitive assay for the functional activity of complement Factor I is described. This 
is based on its third proteolytic clip whereby Factor I cleaves cell-bound iC3b to cell-
bound C3dg and soluble C3c, thereby abolishing conglutination of the cells.  Factor 
H is required as a co-factor for Factor I activity.  Because of the low affinity of iC3b 
for Factor H, the assay needs to be performed at low ionic strength.  This assay is 
easier to perform than those based on the conversion of C3b to iC3b (the first two 
Factor I clips), there being no need for the unstable intermediate EAC142 or for 
purified C3.
Keywords:  Factor I assay; complement C3; conglutination
1.  Introduction
Complement Factor I is the induced-fit enzyme responsible for the C3b breakdown 
cycle of the alternative complement pathway.  Together with co-factors – Factor H, 
membrane co-factor protein (CD46) or CR1(CD35) – it breaks down C3b firstly to 
iC3b, a process which involves two proteolytic cleavages and then to C3c and C3dg 
with a final third clip (Figure 1).  Elevated concentrations of Factor I powerfully down-
regulate the complement alternative pathway (Lachmann and Halbwachs 1975) so 
that measurement of Factor I had become of clinical interest.  
Sensitive functional assays for Factor I have in the past been done using an assay 
for the conversion of C3b to iC3b.  iC3b reacts with the bovine plasma lectin – 
conglutinin (Lachmann 1962) - whereas C3b does not.  This assay therefore 
measures Factor I activity for its first two proteolytic clips of C3b which give rise to 
the formation of iC3b (Figure 1).  There are certain disadvantages to this assay.  It 
requires, on each occasion, a supply of C3 to be reacted with EAC1421 which is 
always a slightly exacting procedure since EAC142 is unstable and purified, native 
C3 has to be used.  If the C3 is highly purified, some Factor H will need to be added.
1 Erythrocyte/antibody reacted with complement components 1, 4 and 2
3To avoid these difficulties, we have developed an assay that looks at the destruction 
of iC3b rather than its formation.  EAC1423bi is easy to make and requires only EA2 
and a human “R3” reagent (made by absorbing fresh normal human serum with 
zymosan or a similar yeast cell preparation). The EAC1423bi is stable for long 
periods and can be shown to be suitable for the assay by demonstrating that it is 
readily agglutinated by conglutinin.  The agglutination produced by conglutinin is 
extremely powerful and for this reason has always been described as 
“conglutination” rather than simply “agglutination”.  The destruction of iC3b by Factor 
I under physiological conditions requires the use of CR1 or a derivative thereof as a 
co-factor.  These are not always readily available.  However, it is well known that the 
failure of other Factor I co-factors, such as Factor H, to catalyze this last clip is due 
solely to their low affinity for iC3b.  This can be overcome by reducing the ionic 
strength and in these circumstances Factor H is a perfectly satisfactory co-factor for 
the last split.  
2.  Materials & Methods
2.1  Reagents
Sheep red blood cells (E) in Alsevers (Oxoid, Product No. SR0053B, Oxoid Limited, 
Wade Road, Basingstoke, Hampshire, RG24 8PW, UK)
IgM anti-sheep E monoclonal antibody (S016 – in house).  Commercial alternatives 
are available (for example from Complement Technology, Inc., 4801 Troup Hwy, 
Suite 701, Tyler, Texas 75703, USA .
Zymosan (Sigma, Product No.  Z4250)
Factor H and Factor I – Complement Technology, Inc., 4801 Troup Hwy, Suite 701, 
Tyler, Texas 75703, USA.  The concentration of Factor I was measured by A280 
extinction coefficient taking 1.40 as extinction at 1 mg/ml Factor I (which includes the 
carbohydrate) (Harrison 1996).
Human R3 (see below)
Bovine conglutinin (prepared in house – see below) 
Complement fixation buffer (CFT) (Oxoid)
Low ionic strength complement buffer is made by diluting one part CFT with 4 parts 
of 5% glucose.
2 Erythrocyte/antibody
4EA is prepared in the standard way by treating sheep E with 5 minimal haemolytic 
doses of antibody SO16 (Harrison 1996).  Pre-prepared EA is available 
commercially, for instance from CompTech Inc.
Human R3 is a reagent developed by the Pillemer laboratory in the 1950s (Pillemer 
et al 1954) depleted of “C’3”, now known to be made up of C3 to C9, and is made by 
treating normal human serum (NHS) with zymosan (yeast cell walls) at 37oC for 45 
minutes as described in detail in Harrison (1996).  Human R3 still contains some C3 
but is depleted of Factor B and usually of C5 and C6.
EAC(1)4(2)3bi is prepared by treating EA with the R3 reagent for 30 minutes at 
37oC.  This changes to EAC43bi upon release of C1 and C2a.  The cells are then 
washed x 3 and finally resuspended to 1% in the low ionic strength complement 
buffer.
Factor H is added to a final concentration of 2µg/ml.
Conglutinin is prepared from 56oC heated bovine serum by absorption onto zymosan 
and elution with EDTA (Lachmann 1962; Lachmann and Richards 1964; Harrison 
and Lachmann 1986).  Alternatively, recombinant conglutinin may be obtained from 
MyBioSource, P.O. Box 153308, San Diego, California, USA.
Antigenic concentration of Factor I was measured using the radial immunodiffusion 
assay system from The Binding Site Group Ltd., 8 Calthorpe Road, Edgbaston, 
Birmingham, B15 1QT.
2.2 Titration of conglutinin
Using CFT with 2 mM calcium, the conglutinin was titrated on EAC43bi cells in a 
microtitre plate (50 µl 1% cells plus 50 µl conglutinin dilution).  The plate was 
incubated at 4oC until settled.  The minimum conglutinating dilution was 1/800 and it 
was decided to use three conglutinating doses for the Factor I assay, i.e. 1/200.  
There are approximately 100,000 conglutinating units per gram conglutinin protein.
2.3 Factor I assay
Factor I was titrated using doubling dilutions of Factor I, starting at 8.45 µg/ml in low 
ionic strength buffer containing gelatin at 1 mg/ml in small glass tubes.   50µl 1% 
EAC43bi/ Factor H cells were added to each tube and incubated for 1 hour at 37oC 
with gentle shaking.  50 µl conglutinin (at 1/200 conglutinin) was then added to each 
5tube and the mixture incubated at 4oC for at least one hour or until the cells had 
settled.  Controls were EAC43bi and no Factor H; Factor I diluted in CFT/gelatin plus 
Factor H (but not low ionic strength).  
The conglutination can be read by settling pattern or, if preferred, by centrifuging the 
cells and resuspending them.  If the cells remain conglutinated it will appear as clear 
liquid with clumps of cells in suspension.  Loss of conglutination results in a cloudy 
liquid.  In this assay it is loss of conglutination that is looked for as evidence of Factor 
I activity.  
The concentration of Factor I in normal human sera was measured using doubling 
dilutions in low ionic strength buffer using the above assay protocol.  Sera collected 
from three different individuals was heat inactivated at 56oC for 30 minutes before 
use.  The control was serum with no added Factor H.
3. Results and Dicussion
The results of the titrations of Factor I and controls are summarised in Table 1 and 
demonstrate that the sensitivity of the assay is high and can measure Factor I down 
to approximately 0.26 µg/ml or 15 ng in 50 µl.  The results of the measurement of 
Factor I in three different normal sera are summarised in Table 2.   This shows that 
absence of conglutination occurs at titres from 1/40 to 1/160 which corresponds to a 
concentration of Factor I is in the region of 10-40 µg/ml which is in agreement with 
other published assays.  The antigenic assays carried out by radial immunoassay 
give slightly higher values, but the suppliers were known to have some problems 
with their reference Factor I level.
A conglutinating assay for the third Factor I clip that cleaves iC3b into C3c and C3dg 
is easier to perform than the assays looking at the earlier clips and the cell 
intermediate used is far more stable. The sensitivity is entirely comparable.
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